Avisa Diagnostics Inc FOGCF

Avisa Diagnostics Inc. is a clinical-stage medical device company. The Company is engaged in the development of the Allora BreathTest (ABT), a drug/device biomarker technology platform. The Allora BreathTest (ABT) is an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load. ABT enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via its own delivery systems. Its ABT portfolio includes Post-Covid-19 Bronchiectasis, Develo, Ventilator-Associated Pneumonia (VAP), Chronic Obstructive Pulmonary Disease (COPD), Community-Acquired, Pneumonia (CAP), Cystic Fibrosis, Tuberculosis, Aspergillus Fungus and Clostridium Difficile (C. diff).

GREY:FOGCF - Post by User

Avisa Diagnostics Inc > Post consolidation

<< Previous

Bullboard Posts

Next >>

Post by Mcgirton Feb 02, 2021 5:21pm

177 Views

Post# 32453000

Post consolidation

Well, there will be 5,225,000 post consolidation shares of FOG plus the 33,263,123 common shares and 14,825,786 restricted voting shares issued to Avisa. Total outstanding for the new company will be 53,313,000 shares.

What will this technology be valued at? It's hard to value the current Avisa as it is private and its technology is considered novel. What would the market cap be?

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for June 17, 2024